

Date: March 12, 2025

To,
The Manager,
Listing Department,
National Stock Exchange of India Ltd.,
Exchange Plaza, Plot No. C-1,
Block G, Bandra Kurla Complex,
Bandra (E),
Mumbai – 400051

NSE Symbol: UNIHEALTH

Dear Sir/ Madam,

Sub: Press Release on UniHealth Hospitals announces Issuance of □10.57 Cr Zero Coupon CCDs to Promoters

In terms of Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, enclosed herewith is a copy of the Press Release made by the Company.

A copy of the press release is also being uploaded on the Company's website: www.unihealthonline.com.

You are requested to take the same on record.

Thanking you,

Yours faithfully,

For Unihealth Hospitals Limited (Formerly Known as Unihealth Consultancy Limited)

Binita Patel Company Secretary & Compliance Officer



UniHealth Hospitals Limited

(Formerly known as Unihealth Consultancy Limited)

CIN No.: L85100MH2010PLC200491



UniHealth Hospitals Announces Issuance of ₹10.57 Cr Zero Coupon CCDs to Promoters

Mumbai, March 12th, 2025: UniHealth Hospitals Limited (NSE – UNIHEALTH): UniHealth - UMC Hospitals Group, a renowned name in global healthcare, with an established presence in Africa and India, has announced the issuance of 7,00,000 Zero Coupon Compulsorily Convertible Debentures (CCDs) at ₹151 each, aggregating ₹10.57 crore, on a preferential basis to its promoters, Dr. Akshay Parmar and Dr. Anurag Shah. The issuance is subject to shareholder approval.

Each CCD will be converted into one equity share of ₹10 at a premium of ₹141 in one or more tranches within 18 months from the allotment date. The promoters will subscribe to equal numbers of CCDs, with 25% of the issue price payable at the time of subscription and the remaining 75% payable upon conversion into equity shares.

Following this capital infusion, Dr. Anurag Shah's stake in the Company will increase from 32.47% to 33.23%, while Dr. Akshay Parmar's holding will rise from 27.14% to 28.14%. This investment underscores the promoters' confidence in the Company's growth trajectory and will support its expansion across the domestic and African markets, further strengthening the UniHealth brand.

Dr. Akshay Parmar, Founder & Managing Director of UniHealth Hospitals, emphasized the significance of this capital infusion, stating, "This investment represents a significant milestone in UniHealth's journey toward expanding our reach and elevating healthcare standards. By strengthening our financial position, we can accelerate our efforts to upgrade medical infrastructure, introduce advanced treatment modalities, and enhance the overall patient experience. Our commitment to unwavering innovation and excellence drives us to create a healthcare ecosystem that is both accessible and world-class. With this initiative, we reaffirm our dedication to delivering superior medical care while expanding our footprint in key regions."

Dr. Anurag Shah, Managing Director overseeing the Group's African operations, highlighted the impact of this initiative, stating, "This investment strengthens our ability to grow and innovate, enabling us to expand our capacity and introduce specialized medical services. With a strong focus on operational efficiency, technology-driven advancements, and patient-centric care, we aim to redefine healthcare delivery in the regions we serve. This investment will empower us to expand existing facilities, introduce specialized services, and drive sustainable improvements in medical accessibility."

About Unihealth Hospitals Limited:

UniHealth Hospitals Limited (NSE – UNIHEALTH), established in 2010 in Mumbai, is a prominent global healthcare service provider with a strong presence in Africa. The company operates in various healthcare sectors, encompassing medical centres, hospitals, consultancy services, pharmaceutical distribution, and medical travel. Under the 'UMC Hospitals' brand, UniHealth manages two multi-speciality facilities with a combined 200-bed capacity in Uganda and Nigeria, along with a dialysis center in Tanzania. Through its subsidiary, UniHealth Pharmaceuticals, it specializes in procuring and exporting pharmaceutical products, serving hospitals in Uganda, Nigeria, and Tanzania.

The Company was successfully listed on the NSE Emerge in September 2023. In FY24, the company reported Revenue of ₹ 50 Cr, EBITDA of ₹ 19 Cr and PAT of ₹ 10 Cr.

Disclaimer:

Certain statements in this document that are not historical facts are forward looking statements. Such forward-looking statements are subject to certain risks and uncertainties like government actions, local, political or economic developments, technological risks, and many other factors that could cause actual results to differ materially from those contemplated by the relevant forward-looking statements. The Company will not be in any way responsible for any action taken based on such statements and undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances.

For Further Information Please Contact Corporate Communication Advisor:



Kirin Advisors Private Limited

Sunil Mudgal – Director sunil@kirinadvisors.com +91 98692 75849 www.kirinadvisors.com